Provided by Tiger Trade Technology Pte. Ltd.

Kairos Pharma, Ltd.

1.64
-0.0200-1.20%
Post-market: 1.650.0099+0.60%19:30 EDT
Volume:99.47K
Turnover:163.89K
Market Cap:5.55M
PE:-0.84
High:1.78
Open:1.71
Low:1.60
Close:1.66
52wk High:9.59
52wk Low:1.51
Shares:3.39M
Float Shares:2.25M
Volume Ratio:0.97
T/O Rate:4.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9469
EPS(LYR):-2.0691
ROE:-113.96%
ROA:-66.91%
PB:1.32
PE(LYR):-0.79

Loading ...

Kairos Pharma’s Bhowmick Presents at Discovery on Target Drug Discovery Conference

Reuters
·
Sep 23

Kairos Pharma Highlights Clinical Strategy in Investor Presentation

TIPRANKS
·
Sep 15

Kairos Pharma CEO John Yu Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 09

Applied Optoelectronics, PDD Holdings And 3 Stocks To Watch Heading Into Monday

Benzinga Earnings
·
Aug 24

Kairos Pharma to Conduct 1-for-7 Reverse Stock Split

MT Newswires Live
·
Aug 22

Kairos Pharma Announces 1-for-7 Reverse Stock Split

THOMSON REUTERS
·
Aug 22

Kairos Pharma Warns NYSE American Compliance Risks Could Trigger Delisting and Damage Investor Confidence

TIPRANKS
·
Aug 14

Kairos Pharma Q2 FY26 Net Loss Narrows to $1.39 Million; Revenue Flat at no Revenue

Reuters
·
Aug 13

Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12

TIPRANKS
·
Jul 28

Analysts Offer Insights on NA Companies: James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (KAPA)

TIPRANKS
·
Jul 24

Kairos Pharma, Bayer partner on prostate cancer therapy

TIPRANKS
·
Jul 22

Kairos Pharma Partners with Bayer to Test Env-105 with Xofigo in Metastatic Prostate Cancer

Reuters
·
Jul 22

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance Xofigo Activity in Metastatic Prostate Cancer

THOMSON REUTERS
·
Jul 22

Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105

TIPRANKS
·
Jul 15

Kairos Pharma Says Phase 1 Env-105 Plus Tagrisso Trial Shows no Grade 3+ Toxicities in 13 Patients

Reuters
·
Jul 15

Kairos Pharma - no Grade 3 or Higher Adverse Events Observed in 13 Patients Treated with Env-105

THOMSON REUTERS
·
Jul 15

Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of Env-105 in Egfr-mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market

THOMSON REUTERS
·
Jul 15

Kairos Pharma Holds Annual Shareholder Meeting, Approves Reverse Stock Split Authorization

Reuters
·
Jul 01

Kairos Pharma outlines mid-year oncology pipeline and funding plans

TIPRANKS
·
Jun 04

Kairos Pharma issues letter from CEO that recaps year, details plans for 2026

TIPRANKS
·
Jun 04